<DOC>
	<DOCNO>NCT01387373</DOCNO>
	<brief_summary>This phase II trial evaluate intra-hepatic chemotherapy oxaliplatin every second week combination systemic capecitabine patient HER2-positive tumour combination trastuzumab ( Herceptin® ) patient non-resectable liver metastasis breast cancer . Only patient without extrahepatic disease include .</brief_summary>
	<brief_title>Intra-hepatic Chemotherapy Patient With Non-resectable Liver Metastases From Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Informed consent Age &gt; 18 year Performance status 01 ; expect survival ≥ 3 month Patient histologically cytologically confirm locally advanced metastatic adenocarcinoma breast Liver metastases suitable local treatment Extrahepatic disease exclude PETCTscan . No progression treatment capecitabine . Prior treatment taxane ( adjuvant metastatic disease ) Metastases &lt; 70 % liver Neutrophile granulocytes &gt; 1.5 x 109/l og thrombocyte &gt; 100 x 109/l Bilirubin &lt; 2.0 x UNL ( upper normal limit ) . Creatinineclearance &gt; 30 ml/min . INR &lt; 1.6 . If patient HER2positive : Baseline LVEF ≥ 50 % . History chemotherapy within 4week period prior start trial medication Other current prior malignant disease except adequately treat cured carcinoma situ cervix squamous cell carcinoma skin . Previous treatment oxaliplatin Cytotoxic experimental treatment within 14 day period start trial medication The patient allow participate clinical trial . Any clinical symptom suggest peripheral neuropathy &lt; equal grade 2 CNS metastasis ( In case clinical suspicion CNS metastases MR CT scan perform within 4 week inclusion Other severe medical condition e.g . severe cardial disease AMI &lt; 1 year Presence diseases prevent oral therapy . • Patients uncontrolled infection Pregnant lactate woman Women capable childbearing use sufficient non—hormonal method birth control Patients able understand treatment collaborate . Prior serious unsuspected reaction treatment fluoropyrimidine Known prior hypersensitivity reaction agent . If patient HER2positive : • Dyspnoea due complication relate malignant disease e.g.lung metastases lymphangitis condition need supportive oxygen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>intrahepatic</keyword>
	<keyword>chemotherapy</keyword>
</DOC>